|
Dec 22
|
Bristol Myers to Buy Karuna Therapeutics in $14 Billion Pharma Deal
|
|
Dec 22
|
Karuna Therapeutics soars after $14 billion takeover by Bristol Myers
|
|
Dec 22
|
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
|
|
Dec 22
|
Bristol Myers acquiring Karuna Therapeutics in $14B deal
|
|
Dec 22
|
5 Things to Know Before The Stock Market Opens
|
|
Dec 22
|
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
|
|
Dec 22
|
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion
|
|
Dec 22
|
Bristol Myers to Buy Karuna Therapeutics for $14 Billion
|
|
Dec 22
|
Bristol Myers to acquire brain drug developer Karuna for $14B
|
|
Dec 8
|
Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue?
|
|
Dec 6
|
Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?
|
|
Nov 30
|
FDA Accepts Karuna's (KRTX) NDA Filing for Schizophrenia Drug
|
|
Nov 29
|
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
|
|
Nov 29
|
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
|
|
Nov 6
|
Karuna Therapeutics, Inc. (NASDAQ:KRTX) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
|
|
Nov 3
|
Q3 2023 Karuna Therapeutics Inc Earnings Call
|
|
Nov 2
|
Karuna Therapeutics Inc (KRTX) Reports Q3 2023 Financial Results and Business Updates
|
|
Nov 2
|
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
|
|
Sep 29
|
Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug
|